Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

Appointments enhance commercialization readiness as Zentalis advances registrational program for azenosertib in...

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was...

Form 8-K - Current report

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now...

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material